On the afternoon of February 27, Professor Shi Yuanyuan, Chairman of our company, Dr. Feng Yaru, Technical director, Sun Rui, Vice Minister of Research and Development Department, and Wei Zheng, assistant chairman of the board, visited Shenzhen Inuo Immune Co., LTD. Wang Mingjun, CEO of Inuo, Qiao Dongjuan, head of cell preparation, and Li Qingqing, head of quality, warmly received and held a symposium.

At the symposium, Professor Shi Yuanyuan, chairman of Shenzhen Cell Valley, introduced the development of Shenzhen Cell Valley in the past six months, including the technological breakthrough of retroviral vector, the construction of the platform for auxiliary declaration, and the improvement of GMP personnel training mechanism. At the same time, the Greater Bay Area regional advantages were utilized. Establish in-depth cooperation with a number of clinical research institutions, scientific research institutions, testing institutions, review institutions and pharmaceutical companies in South China. Shenzhen Cell Valley will be completed in March 2023 cell industry production line 1.0 version, while planning to build an international level of automated, intelligent cell industry 2.0 version production line this summer to meet the different needs of customers. Chairman Shi Yuanyuan said that Shenzhen Inuo is currently the fastest developing TCR-T cell drug development company based on retroviral vector technology in China, and Cell Valley is willing to join hands with Inuo immunization team to declare China's first TCR-T IND approval based on retroviral vector.

Wang Mingjun, Executive president of Innoimmune, made a comprehensive introduction to Innoimmune from the aspects of enterprise development, R&D pipeline and so on, and said that Innoimmune is committed to original innovation, has strong R&D strength, and has been deeply engaged in the field of TCRT for many years, and the virus vector used has always been the retroviral vector, and Shenzhen Cell Valley has the advantages of industrial production of retroviral vector. If the cooperation between the two sides is bound to win, its advantages are not only in the cell product preparation stage, but also reflected in assisting IND application and drug approval. With this symposium as the starting point for cooperation, we will carry out comprehensive cooperation in subject cooperation declaration and product development. The two sides will make good use of their own advantages, integrate resources, create a whole chain industry, promote continuous innovation of domestic cell products based on retroviral vectors, and lead the world!